Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study
What happens when a psychedelic experience continues causing problems long after the trip ends? Emory researchers Josh Lipson and Roman Palitsky discuss psychedelic harms, HPPD, spiritual crisis, adverse events, and the Post-Psychedelic Challenges Study. The post Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study appeared first on Psychedelics Today.
External link. We are not responsible for the content.
Read more βMore From Psychedelics Today
Why Perimenopause Belongs in Psychedelic Research
Perimenopause is one of the least-researched transitions in women's health. Some women are already microdosing San Pe...
Weekly Psychedelic Policy Briefing β August 9, 2026
Jack Gorsline, investigative journalist, covers four federal developments this week. The Department of Veterans Affai...
Ibogaineβs Moment Has Arrived. Are We Ready to Meet It?
MAPS co-executive director Ismail Lourido Ali on what the April 2026 executive order, the Texas and Colorado funding ...
Latest News
Whatβs the difference between recreational and therapeutic psychedelic use? 5 Questions with experimental psychologist Harriet de Wit
De Wit discusses the difficulty of finding out what a drug does, outside of its context.
World Ayahuasca Forum Brings Ancestral Intelligence to Spain
PLUS, an interview with an iconic Grateful Dead artist, ayahuasca and loneliness, and Puerto Rico's executive order. ...
Citizen Science x Phenomenology
Journaling, editing, reflecting, integrating β all remain valid when formalising your anecdotal report, to make sense...
The Psychedelic Future We Were Promised
This Week's Sunday Insider: Why the Psychedelic Future Never Arrived.
Weekly Psychedelic Policy Briefing β August 14, 2026
The FDA has finalized guidance on clinical investigations into psychedelic-assisted therapies and contract research o...
Veterans Affairs continues to drive federal psychedelics push; New FDA guidance; and Resilient Pharmaceuticals tries again for MDMA approval
Plus: Pharmaceutical giant Eli Lilly makes a psychedelics acquisition; Cardiovascular safety is top of mind for psych...